# Trabedersen

Source: https://onco.cc/drugs/trabedersen/  
OnCo record `trabedersen` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Trabedersen is an experimental investigational agent whose form is not stated in the registry from Oncotelic in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.

## Summary

Trabedersen (OT-101) is an investigational agent whose form is not stated in the registry developed by Oncotelic. The sponsor describes its target as TGF-beta2, which OnCo does not yet have a target page for. The sponsor states: An antisense oligodeoxynucleotide complementary to TGF-beta2 mRNA; by suppressing TGF-beta2, which cancers overexpress to cloak themselves from the immune system, it is intended to let innate or therapeutic immunity attack and eliminate the tumour. ClinicalTrials.gov describes the intervention as: OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06079346 (A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer), in pancreatic ductal adenocarcinoma. The largest, NCT06079346, plans to enrol 455 participants with primary completion was scheduled for 2026-06-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: OT-101
- Modality: antisense oligonucleotide (per the sponsor's description; form not stated in the registry record)
- Mechanism: An antisense oligodeoxynucleotide complementary to TGF-beta2 mRNA; by suppressing TGF-beta2, which cancers overexpress to cloak themselves from the immune system, it is intended to let innate or therapeutic immunity attack and eliminate the tumour.

## Sources

- ClinicalTrials.gov: trials of Trabedersen: https://clinicaltrials.gov/search?intr=Trabedersen
- Sponsor pipeline page: https://www.oncotelic.com/pipeline

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Isarna Therapeutics](https://onco.cc/companies/isarna-therapeutics/)
- trials: [A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06079346/)

---
JSON: https://onco.cc/api/v1/entities/trabedersen.json